Macrogenics Inc Surpasses Q2 2025 Estimates with $22.2M Revenue, Narrowed Net Loss and Improved EPS

Macrogenics Inc reported Q2 2025 revenue of $22.2 million, beating estimates of $7.70 million. The company's net loss narrowed to $36.3 million and EPS was -$0.57, better than the estimated -$0.75. Total revenue increased from $10.8 million in Q2 2024, driven by higher contract manufacturing revenue and collaboration revenue. Macrogenics aims to advance its pipeline, form partnerships, and improve its financial position in 2025 and 2026.

MacroGenics Inc. (NASDAQ: MGNX) reported its second-quarter (Q2) 2025 financial results, with GAAP revenue of $22.2 million, surpassing analyst estimates of $7.70 million. The company's net loss narrowed to $36.3 million, and earnings per share (EPS) improved to -$0.57, outperforming the estimated -$0.75 [1].

Revenue growth was driven primarily by higher contract manufacturing revenue and collaboration income. Contract manufacturing revenue (GAAP) increased to $15.4 million from $2.9 million in Q2 2024, while collaboration revenue (GAAP) rose to $6.9 million from $2.2 million in the same period. These gains partially offset the complete loss of product revenue following the exit from MARGENZA in November 2024 [1].

MacroGenics also entered a royalty purchase agreement, assigning future royalties from the cancer immunotherapy ZYNYZ in exchange for a $70 million upfront cash payment from Sagard Healthcare Partners. This deal provided immediate liquidity but retained other economic interests in ZYNYZ, including potential future development, regulatory, and commercial milestones [1].

Research and development expenses (GAAP) decreased to $40.8 million, and selling, general, and administrative expenses (GAAP) fell to $9.3 million, reflecting lower professional fees and the absence of product commercialization costs. The company's cash position declined to $176.5 million as of June 30, 2025, from $201.7 million as of December 31, 2024, but the royalty sale helped offset the cash burn [1].

MacroGenics aims to advance its pipeline, form partnerships, and improve its financial position in 2025 and 2026. The company's lead candidate, lorigerlimab, completed full enrollment in the LORIKEET Phase 2 trial, and the LINNET Phase 2 trial is ongoing. The company plans to present clinical results in the second half of 2025, which could influence future development decisions and potential partnerships [1].

Management did not provide quantitative guidance for revenue or earnings for the remainder of fiscal 2025. However, it expects to maintain funding through the first half of 2027, assuming projected payments from partners and ongoing cost savings [1].

Investors should watch for the outcome of critical regulatory milestones with ZYNYZ and TZIELD, as well as updates on clinical progress for leading pipeline candidates, as these could significantly impact the company's financial outlook [1].

References:
[1] https://www.nasdaq.com/articles/macrogenics-revenue-doubles-q2